Medullary thyroid carcinoma is not the common papillary variety that dominates thyroid cancer statistics and fuels much of the active surveillance debate. It arises from the parafollicular C cells of the thyroid, the cells that produce calcitonin, and it behaves differently from its more indolent cousins. It does not respond to radioiodine therapy, it secretes measurable biomarkers that track its burden, and it can metastasize to cervical lymph nodes early in its course. When such a tumor is caught while still under one centimeter in diameter, it earns the designation of microcarcinoma, and it is precisely in this small, seemingly harmless form that the disease increasingly presents. As ultrasound technology improves and thyroid imaging becomes more common, more of these minute tumors are being found, and clinicians are left with a growing population of patients for whom the natural history is poorly charted.

The research team, led by Yuanmeng Li, Naishi Li, Weigang Zhao, and Xiaolan Lian, combed through their institutional records and identified 75 cases of medullary thyroid microcarcinoma. Within that group, they focused on a subset of 20 patients whose diagnosis and surgical treatment had been delayed and for whom baseline ultrasound imaging of adequate quality existed. For these patients, the observational period before surgery exceeded six months, with a median duration of 27 months. That is a substantial stretch of time for a tumor to do whatever it is going to do, and it gave the investigators a rare longitudinal window into the behavior of an entity that is usually excised quickly and studied only in retrospect.

What the ultrasound scans revealed was striking. Seventy-five percent of the delayed-surgery patients, 15 of the 20, showed sonographic evidence that their microcarcinoma nodules had grown during the observation period, a proportion with a 95 percent confidence interval spanning roughly 53 to 89 percent. When the researchers compared the final nodule volumes with the initial measurements, the difference was statistically robust, with p values below 0.001. In plain terms, these were not static lesions idling in the thyroid gland. During a median of more than two years without intervention, the majority of these tumors expanded, and the volume change was unmistakable rather than a borderline statistical artifact.

Growth alone, however, does not tell a clinician whether a tumor has become more dangerous. To address that question, the team turned to the pathological and biochemical signatures that medullary thyroid carcinoma leaves behind. They stratified their patients using a 5 millimeter threshold, a cut point that divides the microcarcinoma range into its smallest and largest halves. The results were consistent across every measure they examined. Tumors larger than 5 millimeters were associated with higher preoperative levels of calcitonin and carcinoembryonic antigen, the two biomarkers that serve as the workhorses of medullary thyroid cancer surveillance. They also carried a greater incidence of lymph node metastasis, more advanced TNM staging, and a lower rate of biochemical cure after surgery, meaning a lower likelihood that postoperative biomarker levels fell to undetectable territory. Every one of these comparisons reached statistical significance at p values below 0.01.

Correlation analysis reinforced the same story along a continuous gradient rather than a binary divide. Tumor size in this cohort was positively associated with preoperative calcitonin levels, with a correlation coefficient of 0.357 and a p value of 0.022, and with carcinoembryonic antigen levels, which showed an even stronger association at r equals 0.428 and p equals 0.003. Size also correlated with lymph node metastasis at r equals 0.388, with TNM stage at r equals 0.416, and with worse overall outcome at r equals 0.330, the latter with a p value of 0.006. None of these correlations is overwhelming in isolation, and the study’s own authors are careful to note that tumor size and observation time are intertwined in this setting, making it impossible to fully disentangle whether the tumors that grew were intrinsically more aggressive or whether the passage of time itself allowed indolent lesions to progress. But the direction of every association points the same way: bigger tumors, in this disease, mean more disease.

The biological logic behind these findings is worth unpacking. Calcitonin secretion is a function of the number of malignant C cells present, so a growing tumor should, and does, produce a rising biomarker signal. Cervical lymph node metastasis in medullary thyroid carcinoma is known to correlate with primary tumor size, and the 5 millimeter threshold identified here aligns with a broader literature suggesting that risk in this disease accrues continuously rather than in discrete jumps. What makes the new study notable is not that it overturns established biology but that it documents the temporal dimension directly. Most of what is known about medullary thyroid microcarcinoma comes from surgical specimens examined after the fact, snapshots of tumors at the moment of removal. Watching these tumors across a median of 27 untreated months provides something those snapshots cannot: evidence that the clock matters.

The clinical context amplifies the significance. Active surveillance, the strategy of monitoring small thyroid nodules with serial ultrasound rather than operating immediately, has gained genuine traction for papillary thyroid microcarcinoma, where large Japanese cohort studies have shown that the majority of these lesions never grow to a clinically meaningful size. That evidence base has created a certain cultural momentum, a sense among some patients and clinicians that small thyroid cancers in general can be watched safely. The new findings are a pointed reminder that medullary thyroid carcinoma is a different biological entity. There is no equivalent evidence base supporting surveillance for medullary microcarcinoma, and this study now provides the first direct, if retrospective and limited, evidence that waiting carries measurable risk. The authors stop short of claiming that every microcarcinoma will progress, and indeed a quarter of their delayed-surgery cohort showed no growth, but the burden of proof has shifted.

Several caveats deserve honest acknowledgment. The study is retrospective and comes from a single center, which means selection bias is a real possibility; the very fact that these patients experienced delayed diagnosis and surgery suggests their tumors may have been clinically silent or initially mischaracterized, a circumstance that may not generalize to all microcarcinomas. Twenty patients is a small sample, and the confidence intervals around the 75 percent growth figure are correspondingly wide. The authors themselves note that the clinical implications of their findings require confirmation in future studies, ideally prospective ones with standardized imaging intervals and larger, multi-center cohorts. The study was approved by the Ethics Committee of Peking Union Medical College Hospital and conducted in accordance with the Declaration of Helsinki, and it was supported by funding from the Chinese Academy of Medical Sciences, the National Natural Science Foundation of China, and related institutional programs, lending it institutional credibility even as its scale remains modest.

Even with those limitations, the message for clinical practice is difficult to ignore. Medullary thyroid microcarcinoma should not be presumed to remain stable during an untreated interval, the authors conclude, and once the diagnosis is suspected, prompt workup and timely surgery are the prudent default. For a disease that announces itself through calcitonin and CEA, biomarkers that can be measured with a simple blood draw, and that can be imaged with the ultrasound machines already present in every endocrinology clinic, the barriers to early action are low. What this study adds is the urgency: in the roughly two years that separated baseline imaging from surgery for these patients, three quarters of their tumors grew, and the ones that grew larger arrived at the operating room with higher biomarker levels, more nodal disease, more advanced staging, and poorer chances of biochemical cure. Small, in medullary thyroid cancer, does not mean stationary, and the new data suggest that the window in which these tumors are truly micro may be one worth closing deliberately rather than watching drift by.

Subject of Research: Tumor growth and outcomes in medullary thyroid microcarcinoma during delayed surgery

Article Title: Tumor growth in medullary thyroid microcarcinoma during delayed surgery: a single-center study

Article References: Li, Y., Chai, X., Liu, H., Zhang, H., Li, X., Li, B., Chen, X., Zhou, J., Li, N., Zhao, W., & Lian, X. (2026). Tumor growth in medullary thyroid microcarcinoma during delayed surgery: a single-center study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02606-2

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02606-2

Keywords: medullary thyroid microcarcinoma, thyroid cancer, tumor growth, calcitonin, carcinoembryonic antigen, lymph node metastasis, delayed surgery, active surveillance, ultrasound, TNM staging, biochemical cure, endocrine disorders

The research team, led by Hedda Fjell Scheel of the Norwegian University of Life Sciences together with colleagues at Oslo University Hospital and the University of Oslo, took advantage of a publicly available dataset of whole transcriptome sequencing data from canine mammary tumors. After quality control and the removal of animals with incomplete survival records, the final cohort comprised 146 dogs aged between two and nineteen years, representing twenty different breeds. Thirty-eight of these dogs had a recorded time of death after surgery, ranging from one day to 709 days with a median of 205.5 days, while the remaining 108 were right censored, meaning they were still alive at their last follow-up. This substantial censoring proportion, roughly 74 percent of the cohort, posed a genuine statistical challenge that shaped every subsequent analytical decision.

The investigators built three competing Cox proportional hazards survival models. The first, a clinical model, used only variables measurable through standard veterinary workup. The second, a gene expression model, relied exclusively on standardized, pre-filtered transcriptomic features. The third combined both data types. Because the gene expression matrix contained 18,579 genes, vastly more predictors than the 38 survival events available, the team applied careful feature pre-filtering: they retained the 1,000 most variable genes by mean absolute deviation, removed highly correlated pairs above a threshold of 0.95, and selected genes significant in univariate Cox models at a false discovery rate below 0.1. This left forty candidate genes, none of which belonged to the PAM50 subtyping panel used in human breast cancer. Regularized elastic net regression with cross-validated tuning of the alpha and lambda parameters then selected the most informative features for the gene-based models.

Model performance was evaluated with Uno’s C-index, a censoring-robust concordance measure in which 0.5 represents random prediction and 1.0 perfect discrimination, and with time-dependent ROC-AUC at six months, one year, and two years after surgery. Across 100 iterations of Monte Carlo cross-validation with stratified train-test splits of 4:1, the results were strikingly clear. The clinical model achieved a median C-index of 0.646, marginally ahead of the gene expression model at 0.635 and the combined model at 0.621, though none of these differences reached statistical significance. More tellingly, at the clinically critical timepoints of six months and one year after surgery, the clinical model significantly outperformed both transcriptomic models, with a median ROC-AUC of 0.811 at six months compared with 0.727 for the gene expression model and 0.768 for the combined model.

What emerged as decisive were three humble, readily obtainable clinical variables. Stepwise regression favored a multivariate model containing age, lymphatic invasion assessed by tumor histology, and estrogen receptor status evaluated by immunohistochemistry. Lymphatic invasion exerted the largest effect on the hazard of death, confirming its previously reported prognostic power, while estrogen receptor positivity was associated with improved survival, mirroring the pattern well established in human breast cancer. Notably, histopathological grade and molecular subtype, both significant in univariate analyses, dropped out of the multivariate model, likely because they were strongly correlated with lymphatic invasion and estrogen receptor negativity and therefore added no independent information. The final clinical model explained 17.8 percent of the overall variation in survival.

The molecular subtyping analysis itself yielded biologically meaningful results. Using the single-sample MPAM50 classifier, every tumor in the cohort was assigned to either the luminal A or the basal-like subtype, with luminal A accounting for 58.2 percent of samples. Subtype was significantly associated with age, breed, lymphatic invasion, grade, and estrogen receptor status. Basal-like tumors were more frequently grade 2 or 3, more often showed lymphatic vessel invasion, and were overrepresented among estrogen receptor negative tumors, with 69.6 percent of the 23 receptor-negative tumors classified as basal-like. Dogs with luminal A tumors were on average one year younger, and Maltese dogs were more likely to harbor luminal A tumors. These findings indicate that the canine PAM50 subtypes capture tumor biology beyond what estrogen receptor status alone reveals, echoing their prognostic significance in human patients.

Perhaps the most intriguing result came when the researchers used the best-performing clinical model to assign each dog a risk score and split the cohort at the median into high-risk and low-risk groups of 73 dogs each. Survival differed significantly between the groups, with a log-rank p-value of 0.0036. Differential gene expression analysis then uncovered 433 genes significantly differentially expressed between the groups, 279 upregulated in high-risk tumors and 154 in low-risk tumors. Gene set enrichment analysis using the Hallmark collection from the Molecular Signatures Database revealed twenty-four significantly enriched pathways. High-risk tumors were enriched for signatures of proliferation, including E2F targets and the G2M checkpoint, and for metabolic programs such as oxidative phosphorylation and glycolysis, while low-risk tumors showed enrichment of immune-related pathways, including TNF alpha signaling, IL6-JAK-STAT signaling, inflammatory response, and interferon alpha response.

That immune activity marks the low-risk group is a finding with real translational resonance. In human breast cancer, both innate and adaptive immune components are associated with recurrence-free survival, and immune gene expression carries prognostic weight particularly in hormone receptor negative tumors. The canine data suggest that the immune system plays an equally central role in anti-tumor response across species, reinforcing the value of dogs as a comparative model for human breast cancer research. The two diseases share spontaneous onset, histological subtypes, underlying genetic alterations, and gene expression changes, yet molecular markers that transformed human breast cancer management, from PAM50 subtyping to gene expression signatures like MammaPrint, have never been incorporated into routine canine staging. This study represents one of the most systematic attempts to close that gap.

Why, then, did gene expression fail to improve prediction? The authors offer several candid explanations. Adding thousands of transcriptomic features to a small, heavily censored dataset may introduce more noise than signal, a phenomenon documented in large-scale benchmark studies showing that multi-omics survival models are widely sensitive to noise. Linear Cox models may also miss non-linear interactions between genomic and clinical features. Moreover, with only 38 events, statistical power is inherently limited, and a larger number of events might reveal differences that this cohort cannot detect. None of the models exceeded a time-independent C-index of 0.65, which, while comfortably above random, falls short of what would be needed for clinical implementation, though comparable multi-omics studies in humans rarely exceed 0.7 either.

The practical message for veterinary oncology is nonetheless concrete. Estrogen receptor status measured by immunohistochemistry and lymphatic invasion assessed by routine histology could be valuable additions to current TNM staging, potentially refining survival predictions and informing decisions such as whether ovariohysterectomy at the time of tumor removal might benefit a particular patient, since dogs with high serum estradiol and receptor-positive tumors appear more likely to benefit from that intervention. The authors also emphasize the limitations of using overall survival rather than cancer-specific survival in an elderly cohort, and they call for future studies to record cause of death, complete TNM parameters, and richer genomic data. Alternative modeling approaches such as boosting methods and random survival forests may yet extract more from transcriptomic data. For now, the study stands as a sobering and instructive reminder that in the era of big data, the humble microscope slide and the immunohistochemistry stain still hold their ground.

Subject of Research: Machine learning-based identification of prognostic factors for survival in canine mammary gland tumors

Article Title: Unraveling prognostic factors in canine mammary gland tumors using machine learning

Article References: Scheel, H. F., Zobolas, J., Lien, T. G., Lingaas, F., & Bergholtz, H. (2025). Unraveling prognostic factors in canine mammary gland tumors using machine learning. Veterinary Oncology, 2(1), Article 16. https://doi.org/10.1186/s44356-025-00030-7

Image Credits: AI Generated

DOI: 10.1186/s44356-025-00030-7

Keywords: canine mammary tumors, machine learning, Cox regression, gene expression, estrogen receptor, lymphatic invasion, survival prediction, TNM staging, PAM50 subtyping, gene set enrichment analysis, veterinary oncology, precision medicine

The scale of the problem the study addresses is considerable. According to the Global Cancer Statistics 2020 report, roughly 184,615 people worldwide are diagnosed with laryngeal cancer each year, and nearly 100,000 die from it annually. In China alone, projections for 2022 estimated almost 30,800 new cases and about 16,900 deaths. Despite an expanding arsenal of treatments—surgery, radiotherapy, chemotherapy, and combinations tailored to individual circumstances—the five-year overall survival rate has stubbornly hovered between 50 and 60 percent for years. That stagnation, the authors argue, reflects in part the limits of the tools clinicians use to judge prognosis. The TNM staging system, which classifies tumors by their size and local extent, lymph node involvement, and distant metastasis, performs reasonably well when applied to entire populations but falters at the level of the individual patient, where two people with ostensibly identical stage designations can experience dramatically different outcomes.

To build a more discriminating instrument, the researchers turned to the Surveillance, Epidemiology, and End Results database, a vast population-based registry maintained by the United States National Cancer Institute. From records spanning 2000 to 2020, they identified 3,866 patients aged 18 or older with confirmed laryngeal squamous cell carcinoma, applying strict inclusion criteria based on International Classification of Diseases site and histology codes and excluding patients with multiple primary tumors, missing data, diagnoses made only at autopsy, or survival times shorter than three months. The cohort was then randomly split, by computer-generated assignment, into two equal halves: a training cohort of 1,933 patients used to identify prognostic factors and construct the model, and a validation cohort of another 1,933 patients used to test whether the model’s predictions held up in independent data.

The statistical machinery behind the nomogram began with univariable Cox regression analyses, which screened each candidate variable for an association with cancer-specific survival—defined as the interval from diagnosis to death specifically attributable to laryngeal cancer. Variables passing that initial filter were then subjected to multivariable Cox regression, a technique that isolates the independent contribution of each factor while accounting for the influence of all the others. Ten variables emerged as significantly associated with survival: age, race, marital status, primary tumor site within the larynx, tumor size, histologic grade, and the T, N, and M stages of the TNM system, along with whether the patient had undergone surgery on the primary tumor. Each of these factors was assigned a weighted point value in the final nomogram, allowing a clinician to total a patient’s score and read off the estimated probability of surviving one, three, or five years.

The demographic portrait of the cohort underscores the epidemiology of the disease. The overwhelming majority of patients were men over the age of 50—91.83 percent of the sample fell into that age bracket—consistent with the male-to-female incidence ratio of roughly seven to one reported for laryngeal cancer globally. Nearly 80 percent of patients were white, and tumors arose most frequently in the supraglottis, the region above the vocal cords, which accounted for 49.46 percent of cases, followed by the glottis, the vocal cord region itself, at 37.84 percent. Most tumors were moderately differentiated, classified as Grade II, and the vast majority of patients had no lymph node involvement or distant spread at diagnosis. Where distant metastases did occur, the lung was by far the most common site, hosting 64.5 percent of such lesions. During follow-up, 851 patients died of laryngeal cancer, split almost evenly between the two cohorts, with a median survival time of 32 months overall.

The performance metrics of the finished nomogram tell a story of solid, reproducible accuracy. Harrell’s concordance index, or C-index, which measures how well a model ranks patients by risk, reached 0.709 in the training cohort and 0.734 in the validation cohort—figures indicating substantial discriminatory capability. Receiver operating characteristic analysis, which evaluates the trade-off between sensitivity and specificity, yielded area under the curve values of 0.728, 0.746, and 0.766 for one-, three-, and five-year survival predictions in the training cohort, and 0.771, 0.751, and 0.763 in the validation cohort. Calibration curves, generated through 1,000 bootstrapped resampling iterations, showed close alignment between predicted and observed survival probabilities in both cohorts, meaning the model’s confidence in its estimates was matched by real-world outcomes.

Perhaps most striking is how the nomogram fared against the entrenched TNM staging system in head-to-head comparisons. Three complementary statistical approaches all pointed in the same direction. Decision curve analysis, which quantifies the net clinical benefit of a predictive model across a range of decision thresholds, showed the nomogram delivering greater net benefit than TNM staging across a broad spectrum of threshold probabilities in both cohorts. Net reclassification improvement, which measures how many patients are correctly shifted into better or worse risk categories compared with a reference model, reached 0.205, 0.304, and 0.322 at one, three, and five years in the training cohort, and 0.163, 0.203, and 0.182 in the validation cohort. Integrated discrimination improvement, a related metric capturing gains in predictive precision, was likewise positive at every time point. Together, these results suggest the nomogram genuinely adds information that TNM staging alone cannot provide.

Beyond its predictive scores, the tool offers a practical route to risk stratification. Using X-tile software, the researchers established cutoff values of 146 and 247 total points, dividing patients into low-, intermediate-, and high-risk groups. Kaplan-Meier survival curves, analyzed with the log-rank test, revealed starkly divergent survival trajectories among the three strata in both cohorts, with high-risk patients experiencing significantly worse cancer-specific survival. In effect, the nomogram converts a scatter of individual clinical details into a single number that sorts patients into clinically meaningful risk tiers—a capability that could guide decisions about treatment intensity and follow-up frequency for individual patients rather than average ones.

The study’s findings on individual prognostic factors echo and extend earlier research. Older age carried a steeply rising mortality risk, with hazard ratios of 1.82, 2.01, and 3.57 for patients aged 50 to 59, 60 to 69, and 70 and above, respectively, compared with younger patients—a pattern the authors attribute to the cumulative accumulation of environmental exposures over a lifetime and to age-related changes in laryngeal tissue. Black patients faced a significantly elevated risk of death, with a hazard ratio of 1.47, a disparity the researchers link to a complex interplay of genetic predisposition, socioeconomic factors, unequal access to screening and treatment, and differences in health behaviors and environmental exposures. Notably, male sex, often reported as a risk factor in prior studies, did not reach statistical significance here, with a hazard ratio of 1.22 and a P-value of 0.1050—a discrepancy the authors suggest may stem from the limited number of female patients in the cohort.

The authors are candid about the limitations that temper their conclusions. The model was built exclusively on retrospective data from the American population, and the researchers caution that it is not yet mature enough for direct application in Chinese patients given ethnic differences. Crucially, some of the most important risk factors for laryngeal cancer—smoking habits, alcohol consumption, and human papillomavirus infection—could not be incorporated because the SEER database does not capture them, leaving open the possibility that the model’s accuracy could improve further with richer inputs. Prospective data collection, larger and more geographically diverse cohorts, and external validation across different populations remain essential next steps. Still, the study represents a meaningful advance: a convenient, practical, and well-calibrated tool that gives clinicians a sharper lens on individual prognosis at a time when the survival outlook for laryngeal cancer patients has barely moved in decades. For a disease that strikes hardest at older men and disproportionately burdens disadvantaged communities, a better way to see who is truly at risk may be the first step toward changing the numbers themselves.

Subject of Research: Development of a nomogram for predicting cancer-specific survival in laryngeal squamous cell carcinoma using SEER database data

Article Title: A nomogram for predicting cancer-specific survival in patients with laryngeal squamous cell carcinoma: a population-based study from SEER database

Article References: Zhou, H.-L., & Chen, D.-D. (2025). A nomogram for predicting cancer-specific survival in patients with laryngeal squamous cell carcinoma: a population-based study from SEER database. Clinical Cancer Bulletin, 4(1), Article 8. https://doi.org/10.1007/s44272-025-00037-z

Image Credits: AI Generated

DOI: 10.1007/s44272-025-00037-z

Keywords: laryngeal squamous cell carcinoma, nomogram, cancer-specific survival, SEER database, TNM staging, prognostic factors, Cox regression, risk stratification, head and neck cancer, decision curve analysis, C-index, survival prediction

The study, published in the journal Clinical Proteomics, took an unusually personal approach to tumor analysis. Rather than pooling samples and averaging away individual differences, the researchers collected twenty-five matched pairs of tumor tissue and adjacent normal tissue from colorectal cancer patients spanning different stages of the Tumor-Node-Metastasis classification system, the standard framework surgeons and oncologists use to describe how far a cancer has advanced. By analyzing each patient’s tumor against their own healthy tissue, the team could build what they call personalized proteome profiles, capturing the unique molecular signature of every individual’s disease.

The technical engine behind the work was quantitative mass spectrometry, specifically a tandem mass tag labeling strategy coupled with liquid chromatography and high-resolution tandem mass spectrometry. This approach allowed the researchers to measure the relative abundance of thousands of proteins simultaneously across dozens of samples with remarkable precision. The depth of coverage was extraordinary: the team identified more than 12,000 distinct proteins, a figure that approaches the most comprehensive inventories of the human proteome ever assembled and far exceeds what typical cancer proteomics studies achieve.

From this vast dataset, the researchers sifted out differentially abundant proteins, molecules whose levels shifted significantly between tumor and normal tissue and, crucially, whose abundance changed as the disease progressed through increasingly advanced stages. Among the proteins that caught their attention were candidates with well-defined roles in cell biology: annexin A11, a membrane-associated protein implicated in vesicle trafficking; high mobility group box 3, a DNA-binding protein linked to chromatin dynamics; crystallin alpha B, a molecular chaperone with roles in stress response; and flap endonuclease 1, an enzyme central to DNA repair. Others included translocase of outer mitochondrial membrane 34, eukaryotic translation initiation factor 4 gamma 1, and the cell adhesion molecule L1 like protein, each pointing toward distinct vulnerabilities in the cancer cell’s machinery.

One of the study’s most conceptually interesting moves was its treatment of time. Instead of simply cataloging which proteins went up or down, the team clustered the dynamically changing proteins into six distinct profiling patterns, essentially grouping molecules according to the trajectory their abundance followed as tumors advanced. Proteins sharing a pattern, the researchers argue, are likely to be co-opted into the same phase of tumor progression, whether that involves early loss of normal epithelial function, the metabolic rewiring of intermediate disease, or the invasive and metastatic programs of late-stage cancer. This temporal framing transforms a static protein list into something closer to a molecular narrative of how colorectal cancer evolves within a patient.

The functional implications of these patterns were reinforced by pathway analysis. Enrichment of proteins involved in epithelial-mesenchymal transition, the developmental program cancer cells hijack to become mobile and invasive, emerged as a recurring theme, alongside alterations in DNA replication, metabolic pathways, and immune-related signaling. The findings align with and extend earlier large-scale efforts, including work by the Clinical Proteomic Tumor Analysis Consortium and genomic data from The Cancer Genome Atlas, but the personalized, paired-sample design gives the new data a resolution that population-level studies cannot match.

Perhaps the most clinically consequential result came from survival analysis. When the researchers examined progression-free survival, the length of time patients remained free of disease recurrence after surgery, they found a significant correlation between the abundance of their newly identified biomarker candidates and the later appearance of metastasis. In other words, the protein signatures measured in the original tumor tissue carried predictive information about which patients would go on to develop disseminated disease, information that current clinical markers such as carcinoembryonic antigen and carbohydrate antigen 19-9 do not reliably provide.

The candidate biomarkers were not left as abstract mass spectrometry measurements. The team verified their findings using complementary techniques, including immunohistochemistry on tissue sections, confirming that the protein abundance changes observed in the mass spectrometry data could be reproduced with methods already standard in hospital pathology laboratories. That matters enormously for translation: a biomarker that can only be measured in a research-grade mass spectrometry facility faces a long road to the clinic, whereas one that can be detected with an antibody-based stain on a routine biopsy specimen could, in principle, be adopted much more quickly.

Several of the highlighted proteins also suggest mechanistic stories worth pursuing. Flap endonuclease 1, for example, sits at the heart of DNA repair and its overexpression in tumors may help cancer cells tolerate the genomic chaos of rapid division, making it a potential therapeutic target as well as a marker. High mobility group box 3 has been linked to tumor immune evasion and metastatic behavior in other cancers. The cell adhesion molecule L1 like protein connects directly to the epithelial-mesenchymal transition program that underpins invasion and spread. Each of these molecules, the study suggests, may be doing more than passively marking disease stage; they may be active participants in driving it.

The researchers, led by Qi Zhang, Wenyuan Zhu, Jianguo Ji, Minzhe Li, and Qingsong Wang, frame their work as a demonstration of what proteomic technology can reveal about clinically relevant cancer signatures that genomics alone cannot capture. Proteins are the functional workhorses of the cell, and their abundance often diverges from the predictions of gene expression data. By mapping those divergences patient by patient, the study offers both a resource for the broader cancer research community and a concrete shortlist of molecules that could form the basis of new diagnostic tests for metastatic risk. Larger validation cohorts will be needed before any of these candidates reaches the clinic, but the study adds weight to a growing conviction in oncology: the next generation of cancer biomarkers will be written in protein.

Subject of Research: Quantitative proteomic profiling of colorectal cancer tumor progression and biomarker discovery

Article Title: Personalized proteomic analysis of human colorectal cancer identifies novel biomarkers associated with tumor progression

Article References: Zhang, Q., Zhu, W., Ji, J., Li, M., & Wang, Q. (2026). Personalized proteomic analysis of human colorectal cancer identifies novel biomarkers associated with tumor progression. Clinical Proteomics. https://doi.org/10.1186/s12014-026-09633-0

Image Credits: AI Generated

DOI: 10.1186/s12014-026-09633-0

Keywords: colorectal cancer, proteomics, biomarkers, tumor progression, mass spectrometry, metastasis, TNM staging, differentially abundant proteins, epithelial-mesenchymal transition, progression-free survival, tumor biology, Clinical Proteomics